SWX:NOVNPharmaceuticals
Novartis (SWX:NOVN) Has Fresh Attention, What Are Investors Weighing Now?
Novartis (SWX:NOVN) has drawn fresh attention after regulators in Europe issued a positive opinion for expanding Cosentyx into polymyalgia rheumatica, bringing a new potential indication for this franchise to investors’ attention.
The Cosentyx update lands at a time when Novartis has seen mixed momentum, with the share price down about 8.9% over the past month and 5.9% over 90 days, yet still showing a 7.0% year-to-date share price return and a 21.7% total shareholder return over one year...